Molecular Hydrogen Therapy for SLE-PAH: Case Report on Immune Marker Modulation
This case study highlights the potential efficacy of molecular hydrogen therapy in a patient with SLE-PAD and decompensated right-sided heart failure precipitated by sepsis. Further research is needed to confirm its therapeutic benefits, particularly its ability to modulate immune markers and improve clinical outcomes.
Authors
- Yi‐Jung Ho (ORCID: https://orcid.org/0009-0006-3931-2302)
- SHAN-WEN LUI (ORCID: https://orcid.org/0009-0002-1151-6814)
- Thai Hien Tu (ORCID: https://orcid.org/0000-0002-6674-012X)
- KUANG-YIH WANG
- Jeng‐Wei Lu (ORCID: https://orcid.org/0000-0003-2128-2046)
- Feng‐Cheng Liu (ORCID: https://orcid.org/0000-0003-1291-8946)
- TING-YU HSIEH
- Chun‐Hsien Wu (ORCID: https://orcid.org/0000-0003-2205-6403)
Institutions
- University of Copenhagen (DK)
- Tri-Service General Hospital (TW)
- Rigshospitalet (DK)
- National Defense Medical Center (TW)
Publication Details
- Journal
- In Vivo
- Published
- 2025-02-26
- DOI
- https://doi.org/10.21873/invivo.13926
- Citations
- 3
- Primary Topic
- Hydrogen's biological and therapeutic effects
- Type
- article
- Field-Weighted Citation Impact
- 6.02
Funders
- Tri-Service General Hospital
- National Science and Technology Council